Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
SAN FRANCISCO , April 30, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data related to its
Toggle Summary Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
SAN FRANCISCO , April 30, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data related to its
Toggle Summary Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update
- Announced positive interim data in the first three patients dosed in ASPIRO, the Phase 1 / 2 clinical study of AT132 to treat X-Linked Myotubular Myopathy (XLMTM). Plan to dose three additional patients in the first cohort of ASPIRO and to report additional interim data in the second quarter of
Toggle Summary Audentes Therapeutics to Present at the Cowen 38th Annual Health Care Conference
SAN FRANCISCO , March 6, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.
Toggle Summary Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018
-- Conference Call and Webcast to Follow -- SAN FRANCISCO , March 1, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare
Toggle Summary Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day® 2018
SAN FRANCISCO , Feb. 28, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced its support for Rare
Toggle Summary Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
- Preliminary data from VALENS expected to be available in the second quarter of 2018 - Rare Pediatric Disease and Fast Track designations for AT342 granted by FDA SAN FRANCISCO , Feb. 12, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on
Toggle Summary Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
SAN FRANCISCO , Feb. 8, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.
Toggle Summary Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
- AAV8 vector containing a novel hybrid promoter selected based on findings of robust, comparative study in mouse model of Pompe disease - Results presented today at 14th Annual WORLDSymposium 2018 - Plan to file AT982 IND in the second quarter of 2018 - Plan to initiate a Phase 1 / 2 clinical
Toggle Summary Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
- AAV8 vector containing a novel hybrid promoter selected based on findings of robust, comparative study in mouse model of Pompe disease - Results presented today at 14th Annual WORLDSymposium 2018 - Plan to file AT982 IND in the second quarter of 2018 - Plan to initiate a Phase 1 / 2 clinical